AR-V7 positive
|
RCC
|
AR-V7 positive
|
RCC
|
abiraterone acetate Resistant: C3 – Early Trials
|
abiraterone acetate Resistant: C3 – Early Trials
|
AR-V7 positive
|
Prostate Cancer
|
AR-V7 positive
|
Prostate Cancer
|
cabazitaxel Sensitive: C3 – Early Trials
|
cabazitaxel Sensitive: C3 – Early Trials
|
AR-V7 positive
|
Prostate Cancer
|
AR-V7 positive
|
Prostate Cancer
|
docetaxel Sensitive: C3 – Early Trials
|
docetaxel Sensitive: C3 – Early Trials
|
AR-V7 positive
|
Prostate Cancer
|
AR-V7 positive
|
Prostate Cancer
|
abiraterone acetate Resistant: C3 – Early Trials
|
abiraterone acetate Resistant: C3 – Early Trials
|
AR-V7 positive
|
Prostate Cancer
|
AR-V7 positive
|
Prostate Cancer
|
enzalutamide capsule Resistant: C3 – Early Trials
|
enzalutamide capsule Resistant: C3 – Early Trials
|